We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SONN
3001
DELISTED
Sonnet BioTherapeutics
SONN
-18
Closed -$19K
TSLX icon
3002
Sixth Street Specialty
TSLX
$1.82B
-10,800
Closed -$253K
UFPT icon
3003
UFP Technologies
UFPT
$2.53B
-3,410
Closed -$240K
UP icon
3004
Wheels Up
UP
$190M
-58,170
Closed -$51.3M
VERV
3005
DELISTED
Verve Therapeutics
VERV
-5,969
Closed -$220K
VSEC icon
3006
VSE Corp
VSEC
$6.68B
-4,335
Closed -$264K
YARW
3007
Yarrow Bioscience, Inc. Common Stock
YARW
$115M
-21
Closed -$20K
WORX
3008
DELISTED
SCWORX CORP NEW
WORX
-134
Closed -$39K
WPM icon
3009
Wheaton Precious Metals
WPM
$60.2B
-45,800
Closed -$1.97M
YMM icon
3010
Full Truck Alliance
YMM
$9.32B
-235,351
Closed -$1.97M
ZYME icon
3011
Zymeworks
ZYME
$1.78B
-1,714,905
Closed -$28.1M
VIRX
3012
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
-81,136
Closed -$296K
RBCP
3013
DELISTED
RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock
RBCP
-6,381
Closed -$665K
DCPH
3014
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
-311,669
Closed -$3.04M
UGIC
3015
DELISTED
UGI Corporation
UGIC
-8,020
Closed -$831K
CLVT.PRA
3016
DELISTED
Clarivate Plc 5.25% Series A Mandatory Convertible Preferred Shares
CLVT.PRA
-6,709
Closed -$607K
VMW
3017
CALL
DELISTED
VMware, Inc
VMW
-43,500
Closed -$1.06M
APRN
3018
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
-1,225
Closed -$99K
HCCI
3019
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
-1,552,185
Closed -$49.7M
INFI
3020
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
-34,444
Closed -$77K
FRBK
3021
DELISTED
Republic First Bancorp Inc
FRBK
-355,192
Closed -$1.32M
HGEN
3022
DELISTED
HUMANIGEN, INC.
HGEN
-10,069
Closed -$37K
GVCIU
3023
DELISTED
Green Visor Financial Technology Acquisition Corp. I Units
GVCIU
-75,850
Closed -$768K
EUCRU
3024
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
-730,864
Closed -$7.29M
AGRX
3025
DELISTED
Agile Therapeutics
AGRX
-21
Closed -$21K

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.